{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:39:39Z","timestamp":1768250379529,"version":"3.49.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heterologous prime-boost immunization with plasmid DNA and viral vector vaccines is an emerging approach to elicit CD8+ T cell\u2013mediated immunity targeting pathogens and tumor Ags that is superior to either monotherapy. Yet, the mechanisms underlying the synergy of prime-boost strategies remain incompletely defined. In this study, we examine a DNA and adenovirus (Ad5) combination regimen targeting guanylyl cyclase C (GUCY2C), a receptor expressed by intestinal mucosa and universally expressed by metastatic colorectal cancer. DNA immunization efficacy was optimized by i.m. delivery via electroporation, yet it remained modest compared with Ad5. Sequential immunization with DNA and Ad5 produced superior antitumor efficacy associated with increased TCR avidity, whereas targeted disruption of TCR avidity enhancement eliminated GUCY2C-specific antitumor efficacy, without affecting responding T cell number or cytokine profile. Indeed, functional TCR avidity of responding GUCY2C-specific CD8+ T cells induced by various prime or prime-boost regimens correlated with antitumor efficacy, whereas T cell number and cytokine profile were not. Importantly, although sequential immunization with DNA and Ad5 maximized antitumor efficacy through TCR avidity enhancement, it produced no autoimmunity, reflecting sequestration of GUCY2C to intestinal apical membranes and segregation of mucosal and systemic immunity. Together, TCR avidity enhancement may be leveraged by prime-boost immunization to improve GUCY2C-targeted colorectal cancer immunotherapeutic efficacy and patient outcomes without concomitant autoimmune toxicity.<\/jats:p>","DOI":"10.4049\/jimmunol.1502672","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T01:17:35Z","timestamp":1490404655000},"page":"3507-3514","source":"Crossref","is-referenced-by-count":29,"title":["Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells"],"prefix":"10.1093","volume":"198","author":[{"given":"Bo","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University , Philadelphia, PA 19107"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-5875","authenticated-orcid":false,"given":"Trevor R","family":"Baybutt","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University , Philadelphia, PA 19107"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Berman-Booty","sequence":"additional","affiliation":[{"name":"Department of Discovery Toxicology, Bristol-Myers Squibb , Princeton, NJ 08543"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-4618","authenticated-orcid":false,"given":"Michael S","family":"Magee","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University , Philadelphia, PA 19107"},{"name":"Bluebird Bio , Cambridge, MA 02141"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A","family":"Waldman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University , Philadelphia, PA 19107"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1833","authenticated-orcid":false,"given":"Vitali Y","family":"Alexeev","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology, Thomas Jefferson University , Philadelphia, PA 19107"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-4560","authenticated-orcid":false,"given":"Adam E","family":"Snook","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University , Philadelphia, PA 19107"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"key":"2025030615110320400_r1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"2025030615110320400_r2","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3390\/cancers3033114","article-title":"Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines","volume":"3","author":"Weir","year":"2011","journal-title":"Cancers (Basel)"},{"key":"2025030615110320400_r3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/cas.12050","article-title":"Next-generation peptide vaccines for advanced cancer","volume":"104","author":"Yamada","year":"2013","journal-title":"Cancer Sci."},{"key":"2025030615110320400_r4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2025030615110320400_r5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1517\/14712598.2012.704908","article-title":"Clinical development of IMOJEV \u00ae--a recombinant Japanese encephalitis chimeric vaccine (JE-CV)","volume":"12","author":"Appaiahgari","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"2025030615110320400_r6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"2025030615110320400_r7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"2025030615110320400_r8","doi-asserted-by":"crossref","first-page":"174378","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"2025030615110320400_r9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2460\/javma.2005.226.240","article-title":"Immunologic responses to West Nile virus in vaccinated and clinically affected horses","volume":"226","author":"Davidson","year":"2005","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"2025030615110320400_r10","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","article-title":"Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center","volume":"24","author":"Bergman","year":"2006","journal-title":"Vaccine"},{"key":"2025030615110320400_r11","doi-asserted-by":"crossref","first-page":"e106241","DOI":"10.1371\/journal.pone.0106241","article-title":"Sterile immunity to malaria after DNA prime\/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes","volume":"9","author":"Sedegah","year":"2014","journal-title":"PLoS One"},{"key":"2025030615110320400_r12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.clpt.6100369","article-title":"Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen","volume":"82","author":"Snook","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"2025030615110320400_r13","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/0008-5472.CAN-08-3386","article-title":"Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease","volume":"69","author":"Snook","year":"2009","journal-title":"Cancer Res."},{"key":"2025030615110320400_r14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/eji.201444539","article-title":"Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy","volume":"44","author":"Snook","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"2025030615110320400_r15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jnci\/djn178","article-title":"Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity","volume":"100","author":"Snook","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"2025030615110320400_r16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2013.12.043","article-title":"Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C","volume":"88","author":"Witek","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2025030615110320400_r17","doi-asserted-by":"crossref","first-page":"9460","DOI":"10.18632\/oncotarget.2455","article-title":"GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer","volume":"5","author":"Marszalowicz","year":"2014","journal-title":"Oncotarget"},{"key":"2025030615110320400_r18","doi-asserted-by":"crossref","first-page":"G216","DOI":"10.1152\/ajpgi.2001.280.2.G216","article-title":"Effect of E. coli heat-stable enterotoxin on colonic transport in guanylyl cyclase C receptor-deficient mice","volume":"280","author":"Charney","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2025030615110320400_r19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/BF01297193","article-title":"Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes","volume":"32","author":"Guarino","year":"1987","journal-title":"Dig. Dis. Sci."},{"key":"2025030615110320400_r20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1113\/jphysiol.1994.sp020307","article-title":"Segmental differences in the effects of guanylin and Escherichia coli heat-stable enterotoxin on Cl- secretion in human gut","volume":"479","author":"Kuhn","year":"1994","journal-title":"J. Physiol."},{"key":"2025030615110320400_r21","doi-asserted-by":"crossref","first-page":"14827","DOI":"10.1073\/pnas.93.25.14827","article-title":"Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues","volume":"93","author":"Carrithers","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030615110320400_r22","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI57925","article-title":"A uroguanylin-GUCY2C endocrine axis regulates feeding in mice","volume":"121","author":"Valentino","year":"2011","journal-title":"J. Clin. Invest."},{"key":"2025030615110320400_r23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1207675","article-title":"Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior","volume":"333","author":"Gong","year":"2011","journal-title":"Science"},{"key":"2025030615110320400_r24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.humpath.2004.12.002","article-title":"Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract","volume":"36","author":"Birbe","year":"2005","journal-title":"Hum. Pathol."},{"key":"2025030615110320400_r25","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1158\/1078-0432.CCR-06-0865","article-title":"A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer","volume":"12","author":"Schulz","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2025030615110320400_r26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00262-011-1133-0","article-title":"Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C","volume":"61","author":"Snook","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"2025030615110320400_r27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/gt.2013.17","article-title":"Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine","volume":"20","author":"Igoucheva","year":"2013","journal-title":"Gene Ther."},{"key":"2025030615110320400_r28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4049\/jimmunol.156.1.224","article-title":"Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen","volume":"156","author":"Chen","year":"1996","journal-title":"J. Immunol."},{"key":"2025030615110320400_r29","doi-asserted-by":"crossref","first-page":"e1227897","DOI":"10.1080\/2162402X.2016.1227897","article-title":"GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity","volume":"5","author":"Magee","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025030615110320400_r30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"2025030615110320400_r31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.gt.3300847","article-title":"Electropermeabilization of skeletal muscle enhances gene transfer in vivo","volume":"6","author":"Mathiesen","year":"1999","journal-title":"Gene Ther."},{"key":"2025030615110320400_r32","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.4049\/jimmunol.180.8.5300","article-title":"Derivation and fluidity of acutely induced dysfunctional CD8+ T cells","volume":"180","author":"Plesa","year":"2008","journal-title":"J. Immunol."},{"key":"2025030615110320400_r33","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1073\/pnas.1221609110","article-title":"T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy","volume":"110","author":"Zhong","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030615110320400_r34","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"2025030615110320400_r35"},{"key":"2025030615110320400_r36"},{"key":"2025030615110320400_r37","first-page":"243","article-title":"Impact of vaccines universally recommended for children--United States, 1990-1998","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"2025030615110320400_r38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00281-006-0025-4","article-title":"Polyfunctional analysis of human T cell responses: importance in vaccine immunogenicity and natural infection","volume":"28","author":"Makedonas","year":"2006","journal-title":"Springer Semin. Immunopathol."},{"key":"2025030615110320400_r39","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"2025030615110320400_r40","doi-asserted-by":"crossref","first-page":"e87873","DOI":"10.1371\/journal.pone.0087873","article-title":"High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function","volume":"9","author":"Foley","year":"2014","journal-title":"PLoS One"},{"key":"2025030615110320400_r41","doi-asserted-by":"crossref","first-page":"e0118871","DOI":"10.1371\/journal.pone.0118871","article-title":"Clinical outcome of HIV viraemic controllers and noncontrollers with normal CD4 counts is exclusively determined by antigen-specific CD8+ T-cell-mediated HIV suppression","volume":"10","author":"Tansiri","year":"2015","journal-title":"PLoS One"},{"key":"2025030615110320400_r42","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1073\/pnas.96.8.4512","article-title":"Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity","volume":"96","author":"Belyakov","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030615110320400_r43","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1073\/pnas.95.4.1709","article-title":"Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge","volume":"95","author":"Belyakov","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030615110320400_r44","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1172\/JCI5102","article-title":"The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12","volume":"102","author":"Belyakov","year":"1998","journal-title":"J. Clin. Invest."},{"key":"2025030615110320400_r45","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.188.6.1075","article-title":"Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization","volume":"188","author":"Porgador","year":"1998","journal-title":"J. Exp. Med."},{"key":"2025030615110320400_r46","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.4049\/jimmunol.167.10.5549","article-title":"Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization","volume":"167","author":"Cho","year":"2001","journal-title":"J. Immunol."},{"key":"2025030615110320400_r47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/viro.1997.8842","article-title":"Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells","volume":"238","author":"Ambriovi\u0107","year":"1997","journal-title":"Virology"},{"key":"2025030615110320400_r48","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.4049\/jimmunol.176.8.5100","article-title":"CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis","volume":"176","author":"Matsumoto","year":"2006","journal-title":"J. Immunol."},{"key":"2025030615110320400_r49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2025030615110320400_r50","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1128\/JVI.03664-13","article-title":"Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu","volume":"88","author":"Hu","year":"2014","journal-title":"J. Virol."},{"key":"2025030615110320400_r51","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.4049\/jimmunol.178.4.2370","article-title":"Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine\/granzyme B profiles","volume":"178","author":"Ranasinghe","year":"2007","journal-title":"J. Immunol."},{"key":"2025030615110320400_r52","doi-asserted-by":"crossref","first-page":"P450","DOI":"10.1186\/2051-1426-3-S2-P450","article-title":"A phase I study of Ad5-GUCY2C-PADRE in stage I and II colon cancer patients","volume":"3","author":"Snook","year":"2015","journal-title":"J. Immunother. Cancer"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/9\/3507\/62238613\/1502672.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/9\/3507\/62238613\/1502672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:27:36Z","timestamp":1741282056000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/198\/9\/3507\/7954994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1502672","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5]]},"published":{"date-parts":[[2017,5,1]]}}}